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INTRODUCTION: 
Transdermal delivery of drugs through the skin to the 
systemic circulation provides convenient route of 
administration for a variety of  drugs. This route is 
widely used as it is convenient, safe and avoids the GI 
incompatibility, bypassing first pass metabolism, 
enhanced  bioavailability, decreased frequency of drug 
administration. Problem of drug degradation by 
digestive enzymes after oral administration, and 
discomfort associated with parentral drug administration  
can  be  avoided  by this  route. For transdermal delivery 
of drugs, stratum corneum is the main barrier layer for 
permeation of drug moiety and act as a rate limiting 
barrier for penetration of drugs. Hence to increase the 
permeation of drug through skin membrane, different 
approaches of penetration enhancements are used. Drug-
vehicle based enhancement methods such as pro drugs, 
ion-pair, chemical potential of drug, eutectic systems, 
complexation and vesicular systems are used in 
transdermal research as better alternative method to 
enhance permeation of drugs through skin1.  
Vesicular systems such as liposomes  and niosomes are 
promising systems to enhance the drug delivery through 
the skin. They may act as vehicles or as permeation 
enhancers for  drugs to enhance their penetration via 
stratum corneum. Furthermore, they can be used as 
controlled percutaneous drug delivery vehicles. The 
applicability of these vesicular systems is, however, 
limited because of their stability problems. To overcome 
the limitations of vesicular drug delivery, proniosomal 
approach was introduced, which involved a dry product 
or a liquid crystalline gel that could be hydrated 
immediately before use and would avoid many of the 
problems associated with niosomal dispersion and 
problems of physical stability. Proniosomes are non-
ionic based surfactant vesicles used to enhance drug 
delivery in addition to conventional niosomes.  There 
are a number of formulation approaches to resolve the 
problems of low solubility and low bioavailability. 
Proniosome technology offers novel solution for poorly 
soluble drugs2. 
Candesartan cilexetil (CC) is an esterified prodrug of 
candesartan, a non-peptide angiotensin II  receptor 
antagonist used in the treatment of hypertension. This 
medication is also used to treat congestive heart failure. 
This drug may also be used to help protect the kidneys 
from damage due to diabetes. The  major drawback in 
the therapeutic application and efficacy of Candesartan 
cilexetil as an oral dosage form is its very low aqueous 
solubility (0.003 mg/mL) and very low oral 
bioavailability i.e. only 15% 3. 
Some efforts have been made to enhance the solubility 
of candesartan cilexetil to study its effect on the 
bioavailability of the drug. A self emulsifying drug 
delivery systems (SEDDS) have been developed by M. 
Sunitha Reddy  et al 4  to enhance the solubility, 
diffusion rate and oral bioavailability of candesartan 
cilexetil. The solubility of candesartan cilexetil in 
different media Tween 80, Sodium dodecyl sulfate, 
Macrogol 6000, Sodium carboxymethyl cellulose and 
Sodium carboxymethyl dextran has been reported by  
Eliska Vaculikova et al 5.Fast dissolving tablets of 
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Candesartan cilexetil by using Novel co-processed 
superdisintegrants  have   been developed by S.B. 
Shirsand et al6  to increase the solubility and dissolution 
rate of drug. 
The aim of this study is to investigate the feasibility of 
formulation of proniosomes of Candesartan cilexetil. 
Vesicles prepared were characterized by optical, 
scanning electron microscopy for vesicle formation and 
morphology. Drug encapsulation efficiency and release 
studies were carried out. Finally, a stability study of 
proniosomal formulations was also performed to 
investigate the leaking of the drug during storage. 
MATERIALS AND METHODS: 
Materials 
Candesartan cilexetil was obtained as gift sample from 
Hetero pharmaceuticals (Hyderabad). Span 60, Span 40, 
Span 20 and Span 80 were procured from Loba 
chemical  pvt. Ltd, Mumbai. Tween 20,tween 80 and 
Cholesterol were procured from SD. fine. chemicals  
limited, Mumbai. Soya lecithin was procured from Hi 
media laboratories PV..Ltd. Mumbai. Absolute  ethanol 
and Potsium dihydrogen phosphate were procured from 
Merck-specialities pvt. Ltd,Mumbai. Sodium hydroxide 
was purchased from Thermo fischer scientific india 
pvt.Ltd, Mumbai. 
Drug – Excipients Compatability studies by FT-IR 
spectroscopy 
Fourier-transform infrared (FTIR) spectrophotometer 
was used for infra-red analysis of samples to interpret 
the interactions of drug with non-ionic surfactants and 
other ingredients. The powdered samples were used for 
FTIR studies. Infrared (IR) spectra were obtained on a 
Bruker 1.2.4 IR system (software OPUS 7.0) using the 
Attenuated Total Reflectance Spectroscopy method. The 
scanning range was 400-4000 cm-1. The FT-IR spectra 
of drug with Non- ionic surfactants,soya lecithin and 
cholesterol blends were compared with the FT-IR 
spectrum of pure drug.  
Solubility studies
 
The solubility of Candesartan cilexetil was determined 
in water and different pH buffers (phosphate buffer of 
pH 6.5, pH 6.8 and pH 7.4) and phosphate buffer of pH 
6.5 containing different amount of solubilizer (0.3%, 
0.35%, 0.4%, 0.5% and 0.7% tween20) and the results 
revealed that, solubility of Candesartan cilexetil was 
more in phosphate buffer of pH 6.5 containing 0.35% 
tween20. 
Preparation of Transdermal proniosomal gel  
Proniosomal gel of candesartan cilexetil was prepared 
by coacervation phase separation technique. Drug and 
required quantities of materials viz surfactant, soya 
lecithin and cholesterol as per the specified ratio were 
taken in a dry, clean, wide mouthed test tube. A 
measured amount of ethanol (absolute alcohol) was 
added to test tube to dissolve the ingredients. The open 
end of test tube was covered with a lid to prevent loss of 
solvent from it and warmed over water bath at 60-700C 
for about 5 minute until the surfactant mixture was 
dissolved completely. Then the aqueous phase 
(phosphate buffer of pH 6.5 containing 0.35% tween 20) 
was added and warmed on a water bath till a clear 
solution was formed. The clear solution formed was 
cooled to room temperature to convert it to a gel known 
as Proniosomal gel. The gel obtained was preserved in 
the same glass tube in a dark for characterization 
7.Composition of   proniosomal gel formulations were 
given in Table 1. 
 
Table 1: Composition of   proniosomal gel formulations  of candesartan cilexetil 
Ingredients FORMULATION CODE 
PN
F1 
PNF
2 
PNF
3 
PNF
4 
PNF
5 
PNF
6 
PNF
7 
PNF
8 
PNF
9 
PNF1
0 
PNF1
1 
PNF1
2 
Candesartan 
cilexitil (mg) 
20 20 20 20 20 20 20 20 20 20 20 20 
Span 60(mg) 180 _ _ _ _ _ 180 _ _ _ _ _ 
Span 40(mg) _ 180 _ _ _ _ _ 180 _ _ _ _ 
Span 20(mg) _ _ 180 _ _ _ _ _ 180 _ _ _ 
Span 80(mg) _ _ _ 180 _ _ _ _ _ 180 _ _ 
Tween 20(mg) _ _ _ _ 180 _ _ _ _ _ 180 _ 
Tween 80 (mg) _ _ _ _ _ 180 _ _ _ _ _ 180 
Soya 
lecithin(mg) 
180 180 180 180 180 180 180 180 180 180 180 180 
Cholesterol(mg) 20 20 20 20 20 20 40 40 40 40 40 40 
Ethanol(ml) 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
Phosphate 
buffer of pH 6.5 
containing 
0.35% tween20 
(ml) 
0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
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Characterization of Proniosomal gel 
Physical appearance of proniosomal gel
8
 
The prepared gel was viewed through naked eye to 
characterize color and physical state of gel. Proniosomal 
gel was also viewed by optical microscope at 40 X 
magnification, to observe crystal characteristics of gel 
by spreading as a thin layer on a slide and placing the 
cover slip on it. The appearance of each formulation was 
checked for its color, consistency and fluidity.  
Vesicle Size Analysis
9
 
Size and size distribution studies were done for 
niosomes obtained after hydration of proniosomal gel 
with agitation (shaking) and without  agitation. Size 
analysis was done by adding 10ml of phosphate buffer 
of pH 6.5 containing 0.35% tween 20  to the 
proniosomal gel (100mg) in a small glass vial with 
occasional shaking for 10 min. After hydration, the 
dispersion of niosomes was observed under optical 
microscope at 40x magnification. The sizes of 100 
vesicles were measured using a calibrated ocular and 
stage micrometer fitted in a optical microscope. 
Vesicle morphology
10
 
Shape  and surface morphology of proniosomes was 
studied using scanning electron microscopy (SEM).  
The niosomes formed from the hydration of 
proniosomal gel were mounted on an aluminum stub 
with double-sided adhesive carbon tape. The vesicles 
were then sputter-coated with gold/palladium using a 
vacuum evaporator and examined with the scanning 
electron microscope equipped with a digital camera at 
10kV accelerating voltage. 
pH determination
11
 
The proniosomal gel was made into niosomal 
suspension. Then the pH of niosomal suspension was 
determined using pH meter.  
Drug encapsulation efficiency determination
12 
 Proniosomal gel (0.2 g) was reconstituted with 10 ml of 
phosphate buffer of pH 6.5 containing 0.35% tween 20 
in a glass tube. The aqueous suspension was sonicated 
in a bath sonicator for 15 min. The candesartan cilexetil 
containing niosomes were separated from unentrapped 
drug by centrifugation at 15000 rpm at 20°C for 90 min.  
The supernatant was taken and diluted with phosphate 
buffer of pH 6.5 containing 0.35% tween20 and the free 
drug concentration in the resulting solution was assayed 
by  UV spectroscopic method at 257nm. The percentage 
of drug encapsulation was calculated by using the 
following equation. 
EP (%) = [(ct - cr)/ct] × 100 
 Where EP is the encapsulation percentage, Ct is the 
concentration of total drug, and Cr is the concentration 
of free drug. 
In-Vitro drug diffusion study 
13 
The in-vitro release studies on proniosomal gel were 
performed using Franz-diffusion cell. The capacity of 
receptor compartment was 10 ml. The area of donor 
compartment exposed to receptor compartment was 1.88 
cm2. The membrane was mounted between the donor 
and receptor compartment. A weighed amount of 
proniosomal gel equivalent to 20mg drug was placed on 
one side of the membrane. 10 ml of phosphate buffer of 
pH 6.5 containing 0.35% tween 20 was taken as receptor 
medium. The receptor compartment was surrounded by 
a water jacket to maintain the temperature at 37±1ºC. 
The receptor fluid was stirred by a Teflon-coated 
magnetic bead fitted to a magnetic stirrer at a speed of 
600 rpm.  Samples were withdrawn at regular intervals ( 
1, 2, 3, 4,5, 6,7, 8,9, 10, 11, 12, and 24 h). At each 
sampling interval, 1 ml samples were withdrawn and 
were replaced by equal volumes of fresh receptor fluid. 
Sink condition was maintained throughout the 
experiment. Samples withdrawn were suitably diluted 
and analyzed spectrophotometrically at 257 nm.  
Release kinetics
14
 
To study the release kinetics, data obtained from in vitro 
diffusion studies was fitted in various kinetic models: 
zero order as cumulative percent of drug release vs. 
time, first order as log cumulative percentage of drug 
remaining vs. time, Higuchi’s model as cumulative 
percent of drug release vs. square root of time and 
Erosion model as cubic root of the unreleased fraction of 
the drug versus time. To determine the mechanism of 
drug release, the data was fitted into Korsmeyer and 
Peppas equation as log cumulative percentage of drug 
released vs. log time, and the exponent n was calculated 
from slope of the straight line. The value of n 
characterizes the release mechanism of drug, if exponent 
is 0.5, then diffusion mechanism is fickian; if 0.5< n 
<0.89, mechanism is non- fickian, n = 1 to Case II 
(relaxational) transport, and n > 1 to super case II 
transport. 
Preparation of wistar rat skin for permeation 
studies
1,11,15
 
In the present study, wistar albino rat abdominal skin 
was used. Ex vivo skin permeation studies were carried 
out with Institutional Animal Ethical Committee 
approval (Approval Number: HCOP/IAEC/2013-14/01). 
After the animal was sacrificed, the abdominal skin was 
shaved lightly with an electrical clipper (before of which 
a depilatory cream was applied) taking care to prevent 
any damage to the surface of the skin, then the 
abdominal skin was excised from the animal using a 
sharp blade and surgical scissors. The skin was lifted 
easily from the animal after incision was made. The skin 
was defatted by wiping it with a cotton tip soaked in 
diethyl ether to remove the subcutaneous fat and 
scraping the dermal side to remove the muscle and 
blood vessels. The skin was wiped again with a cotton 
tip soaked in ether to prevent any adhering fat. The skin 
so prepared was wrapped in aluminium foil and stored 
in a deep freezer at (2-5°C) till further use. The skin was 
defrosted at room temperature when required.  
Ex- Vivo  drug permeation studies
 
The selected formulations on the basis of entrapment 
efficiency, and in vitro drug release were subjected to 
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permeation studies through rat skin using Franz 
Diffusion cell. Before starting the experiment, the skin 
was kept in phosphate buffer pH 7.4 for about 1 hour in 
a water bath at constant temperature of 37 ºC to allow 
water soluble UV absorbing material to leach out. The 
effective permeation area of the diffusion cell  was 1.88 
cm2. 10 ml of  phosphate buffer of pH 6.5 containing 
0.35% tween 20 was taken as receptor medium. Excised 
skin was mounted between the donor and the receptor 
compartment with stratum corneum side facing upwards 
into the donor compartment. The donor compartment 
was left open and wrapped with cellophane to prevent 
contamination of the formulation from the atmosphere, 
A weighed amount of proniosomal gel equivalent to 
20mg drug was placed on the surface of the skin.  
Temperature was maintained at 37±1ºC using water 
bath. The receptor chamber contents were magnetically 
stirred at 600 rpm.  Samples were withdrawn at regular 
intervals (1, 2, 3, 4,5, 6, 7,8, 9,10, 11,12,  and 24 h),  and 
analyzed for drug content spectrophotometrically at 257 
nm. Cumulative amount of drug permeated through the 
skin (µg/cm2) was plotted as a function of time (t) for 
each formulation.  
The skin flux (J)(μg/cm2/h),was determined from the 
slope of linear portion of the cumulative amount 
permeated per unit area versus the time plot. 
Permeability coefficient (Kp) (cm/h),  was calculated by 
dividing J with the concentration of the drug in donor 
cell (C0) by using the following equation: 
Kp = J/C0 
The skin flux can be experimentally determined from 
the following equation     J = (dQ/dt)  /A 
     where J  is flux (μg/cm2 per h), A: Area of skin tissue 
(cm2 ) through which drug permeation  takes place, 
(dQ/dt) is the slope. 
Short term stability studies
16 
Stability studies were conducted for the best formulation 
i.e. PNF7 of candesartan cilexetil proniosomal gel. The 
ability of vesicles to retain the drug (Drug Retention 
Behaviour) was assessed by keeping the proniosomal 
gel at three different temperature conditions, i.e., 
refrigeration temperature (4-80C), room temperature 
(25±20C) and oven maintained at (45±20C). Throughout 
the study, proniosomal formulation was stored in 
aluminium foil-sealed glass vials.  The stored 
formulation was analyzed for particle size & percent 
drug entrapment. 
RESULTS AND DISCUSSIONS 
Drug – Excipients Compatability studies 
The FTIR spectra of pure candesartan cilexetil and 
physical mixture of drug with excipient is shown in Fig. 
1(a),(b). The presence of peaks at 2932.65 cm
-1  
(Aromatic C-H stretching), 1115.95 cm-1 (C-N 
stretching), 3610.80 cm-1(N-H stretching), 1752.10 cm-
1(C=O stretching), 746.98 cm-1(Aromatic C-H bending), 
2858.18 cm-1 (Aliphatic C-H stretching), 1241.41 cm-1 
(C-O-C)  were characteristic to the pure candesartan 
cilexetil. IR spectrum of physical mixture of drug with 
excipients revealed that there was no appreciable change 
in position and intensity of peak with respect to IR 
spectrum of pure candesartan cilexetil. IR analysis 
revealed that there was no known chemical interaction 
between drug and excipients.  
 
Fig 1(a): FT-IR spectrum of pure drug candesartan cilexetil 
 
Fig 1(b): FT-IR spectrum of physical mixture of drug 
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Vesicle morphology  
The morphology of niosomes derived from proniosomal 
gel was studied using Scanning Electron Microcopy. 
SEM imaging of candesartan cilexetil revealed that the 
niosomes produced  from  hydration of proniosomes  
were spherical  in shape  and discrete with sharp 
boundaries having large internal aqueous space. SEM 
imaging of niosome produced from  optimized 
formulation PNF7 was  shown in Fig 2. The optical 
microscopy images of the niosomes prepared from 
different proniosomal formulations are shown in Fig 3. 
 
 
(a)                                                             (b) 
 
(c)                                                                 (d) 
Fig 3 (a),(b),(c),(d): Optical microscopic images of proniosomal gel formulations 
 
 
Fig 2: SEM images of optimised formulation (PNF7) 
 
Physical  appearance of proniosomal gel 
Proniosomal gel of candesartan cilexetil  prepared with 
Span (40, 60) have pale yellow semi solid gel like 
appearance. Proniosomal gel produced from Span 20 
have thick sticky gel like appearance and span 80 have 
light brownish gel like appearance. Proniosomal gel of 
tween 20 appears as Yellow highly viscous liquid form 
and proniosomal gel of Tween 80 appears as semisolid 
crystalline gel. The results are reported in Table 2. 
Vesicle size analysis  
Mean Vesicle size of candesartan cilexetil  
proniosomes was presented in Table 2, which indicated 
that vesicles formed with  Spans were  smaller in size 
than vesicles formed with Tweens. The relationship 
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observed between niosome size and Span 
hydrophobicity has been attributed to the decrease in 
surface energy with increasing hydrophobicity, 
resulting in the smaller vesicles. This would also 
explain the large vesicle size of niosomes prepared 
with Tween which has a much lower hydrophobicity 
than Span. Increasing the cholesterol content also 
contributed an increase in the hydrophobicity, with a 
subsequent slight reduction in vesicle size. The 
differences in vesicle size among the niosomes 
prepared with Span were not significant. The  Size of 
vesicle was reduced when dispersion was agitated due 
to breakage of larger vesicles to smaller vesicles.  
pH  determination  
Skin compatibility is the primary requirement for a 
good topical formulation. It was found that the pH of 
all the formulations were in the range of 5.64 to 7.20, 
which  suits the skin pH, indicating skin compatibility. 
The results of pH determination are reported in Table 
2. 
Drug encapsulation efficiency  
Encapsulation efficiency of   proniosomal gel 
formulations ranged from 80.40% to 92.20%. The drug 
encapsulation efficiency of twelve formulations were 
shown in Table 2.and Fig 4.  
As shown in Table 2, Encapsulation efficiency of 
proniosomes formed from Span 60, Span 40, Span20, 
and Span 80 was found high compared with 
proniosomes prepared from Tweens (Tween 20, Tween 
80). Among the spans, Span 60 have higher 
encapsulation efficiency due to the   longer saturated 
alkyl chain compared to that of span 40,span 20 and 
span 80.Most of the surfactants used to make nonionic 
surfactant vesicles such as spans have a low aqueous 
solubility. However, freely soluble nonionic surfactants 
such as Tween can form the micelles on hydration in 
the presence of cholesterol.  The tween formulations in 
the present study were also able to entrap candesartan 
cilexetil efficiently. However the encapsulation 
efficiency was relatively low compared to those 
composed of Span. This is because the vesicles can be 
successfully formed by Tween only in the presence of 
excess cholesterol. 
 As the cholesterol content of the formulation 
increased, the encapsulation of drug also increased. 
The formulations (PNF7-PNF12) containing 9:9:2 ratio 
of surfactant : soya lecithin : cholesterol showed high 
encapsulation efficiency compared to the formulations 
(PNF1-PNF6) containing 9:9:1 ratio of surfactant:soya 
lecithin  :cholesterol. 
 
Table 2: Characterization of proniosomal formulations for physical appearance,  pH, Vesicle size and 
Encapsulation Efficiency. 
*All values represent mean±standard deviations(SD), n=3 
 
Formulation 
code 
Physical appearance pH Mean vesicle size (µm) Encapsulation 
efficiency* 
Without 
agitation* 
With 
agitation* 
 
 
PNF1 Pale yellow semi solid gel 5.89 25.06 ± 0.50 5.97 ± 0.55 85.83 ± 0.67 
PNF2 Pale yellow semi solid gel 5.97 24.89 ± 0.40 6.54 ± 0.67 87.65 ±0.47 
PNF3 Yellow semisolid thick sticky gel 6.2 19.82 ± 0.16 9.48 ± 0.77 85.79±0.85 
PNF4 Light Brownish gel 6.6 17.41 ± 0.94 7.57 ± 0.11 84.08 ± 0.32 
PNF5 Yellow highly viscous liquid 5.82 22.50 ± 0.58 8.5  ± 0.23 82.45 ± 0.45 
PNF6 Yellow semisolid crystalline gel 7.1 20.95 ± 0.96 10.64 ± 0.89 80.40 ± 0.87 
PNF7 Yellowish semisolid gel 6.80 24.65 ± 0.12 4.27  ± 0.43 92.29 ± 0.56 
PNF8 Yellowish semisolid gel 6.30 22.58  ± 0.19 5.54  ± 0.38 90.21± 0.98 
PNF9 Yellow semisolid thick sticky gel 5.64 20.62  ± 0.86 7.98  ± 0.92 89.56 ± 0.22 
PNF10 Light Brownish gel 7.2 18.56  ± 0.54 6.19  ± 0.45 86.24 ± 0.34 
PNF11 Brownish semisolid compact mass 6.7 16.22  ± 0.84 7.2  ±  0.67 84.18 ± 0.73 
PNF12 Yellow semisolid crystalline gel 6.56 19.45  ± 0.26 9.28  ± 0.87 82.65 ±0.99 
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Fig 4: Comparision of entrapment efficiency of 
proniosomal gel formulations 
In vitro drug diffusion studies 
The results indicated, that PNF1 containing span 60 had 
shown higher drug release profile than other 
formulations, because niosomes prepared with tweens 
and other spans were significantly larger than those 
prepared with Span60. Proniosomes of Span 60 were 
smaller in size, demonstrated higher hydrophobicity and 
higher surface area due to low vesicle size and hence 
better permeability of drug has occured. Higher drug 
permeation was seen from niosomes prepared with Span 
60 than from the other surfactant. This could be due to 
the emulsification effect of the surfactant after the 
hydration of the proniosome by the diffusion medium 
and formation of  channels within the gel structure due 
to loss of lipid bilayer. Drug released from proniosomes 
prepared with tweens showed lesser extent of drug 
release compared to that prepared with span. It might be 
due to the larger size of the vesicles and less lipophilic 
nature of the Tween, which makes it more difficult for 
these vesicles to penetrate or fuse with membrane 
whereas the inclusion of Span which is more lipophilic 
than Tween further increased the lipophilicity of the 
drug leading to better penetration. 
Formulations which have higher cholesterol content 
(PNF7-PN12) showed less drug release over a period of 
24 hrs. Increase in cholesterol ratio resulted  in a more 
intact lipid bilayers as a barrier for drug release and 
decreased its leakage by improving the fluidity of the 
bilayers membrane and reducing its permeability, which 
led to lower drug elution from the vesicles.
 
 
Fig. 5: In vitro drug release profiles  of candesartan cilexetil from PNF1-PNF6 proniosomal  gel formulations 
 
 
Fig. 6: In vitro drug release profiles of candesartan cilexetil from PNF7-PNF12 proniosomal gel formulations 
 
0
20
40
60
80
100
P
N
F1
P
N
F2
P
N
F3
P
N
F4
P
N
F5
P
N
F6
P
N
F7
P
N
F8
P
N
F9
P
N
F…
P
N
F…
P
N
F…%
 e
n
ca
p
su
la
ti
o
n
 e
ff
ic
ie
n
cy
formulation code
0
20
40
60
80
100
0 5 10 15 20 25 30
%
 c
a
n
d
es
a
rt
a
n
 c
il
ex
et
il
  
re
le
a
se
d
Time (hr)
PNF1
PNF2
PNF3
PNF4
PNF5
PNF6
0
20
40
60
80
100
0 5 10 15 20 25 30
%
 c
a
n
d
es
a
rt
a
n
 c
il
ex
et
il
 
re
le
a
se
d
Time (hr)
PNF7
PNF8
PNF9
PNF10
PNF11
PNF12
Pinnika et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(2), 90-98 97 
© 2011, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                               CODEN (USA): JDDTAO 
 
In vitro drug release kinetics 
In vitro drug release profile of each formulation was 
fitted in to different equations and kinetic models to 
explain the release kinetics of candesartan cilexetil from 
proniosomal gel. When the R2  values of regression plots 
for first order and zero order were considered, R2 values 
of zero order plots were found to be higher than first 
order plots. Hence it is evident that the drug release 
from all candesartan cilexetil proniosomal gel 
formulations, followed zero order kinetics. By 
incorporating release data in Higuchi and Erosion 
models, the R2 values of all the formulations were found 
to be greater for higuchi model. So all the formulations 
in this study were best expressed by higuchi’s  classical 
diffusion equation. The linearity of plot indicated that 
the release process was diffusion controlled. To further 
confirm the exact mechanism of drug release, the data 
was incorporated in to  kores meyer peppas  model and 
the mechanism of drug release was indicated according 
to the value of exponent ‘n’. For all the proniosomal gel 
formulations the release exponent ‘n’ value found to be 
between 0.5 to 0.89. This indicates the drug released 
from all the proniosomal gel formulations followed 
non–fickian diffusion. In vitro drug release data was 
best fitted in higuchi and kores -meyer peppas equation 
showing that the drug release was controlled mainly by 
diffusion mechanism. 
Ex- Vivo  drug permeation studies 
The ex vivo permeation of Candesartan cilexetil through 
rat abdominal skin from  proniosomal gel formulations 
was determined using Franz diffusion cell. Six 
proniosomal gel formulations were selected based on 
high encapsulation efficiency and in vitro drug release. 
The selected proniosomal formulations (PNF1, PNF2, 
PNF4, PNF7, PNF8, PNF10) were characterized for 
their drug permeation through rat abdominal skin. The 
cumulative amount of candesartan cilexetil permeated 
per unit area across excised rat skin as the function of 
time, flux and permeability  coefficient were 
determined.  
Increasing the cholesterol content resulted in a more 
intact lipid bilayer as a barrier for drug permeation and 
decreased its leakage by improving the fluidity of the 
bilayer membrane and reducing its permeability, which 
led to lower drug elution from the vesicles. Among all 
the formulations, PNF1 showed higher drug permeation 
81.3±0.76% in 24 hrs with a flux value of 1.90±0.13 
µg/cm2 /hr and permeability coefficient of  0.095±0.18 
cm2  /hr. 
 
Table 3. Flux and Permeability co efficient of  Candesartan cilexetil   proniosomal gel formulations 
Formulation 
code 
Flux (µg/cm
2
 /hr)
 *
 Permeability coefficient 
(cm
2  
/hr)* 
PNF1 1.90±0.13 0.095±0.17 
PNF2 1.87±0.19 0.088±0.16 
PNF4 1.84±0.17 0.087±0.13 
PNF7 1.89±0.09 0.094±0.18 
PNF8 1.84±0.12 0.092±0.15 
PNF10 1.79±0.15 0.089±0.11 
* All values represent mean±standard deviations(SD), n=3 
Short term Stability studies 
Short term Stability studies were conducted for the 
optimised formulation (PNF7) of Candesartan cilexetil 
proniosomal gel at room temperature (30 ± 2°c), at 
refrigerator temperature (4 ± 2°c),and oven maintained 
at 45±20c for a period of 2 months. There was no 
significant change in relation to vesicle size and 
encapsulation efficiency. The results are given in Table 
4.
 
Table 4. Stability study data of optimized formulation (PNF7) 
S.No.  Temp.  Initial After 2 months 
Vesicle 
size* 
Encapsulation 
efficiency* 
Vesicle 
size* 
Encapsulation 
efficiency* 
1 4-80c 4.27±0.43 90.60 ± 0.56 4.37±0.67 89.01±0.46 
2 25±20c 4.27±0.43 90.60 ± 0.56 4.98±0.34 86.32±0.56 
3 45±20c 4.27±0.43 90.60 ± 0.56 5.12±0.95 80.73±0.32 
* All values represent mean±standard deviations(SD), n=3 
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CONCLUSION: 
In the present work, an attempt had been made to 
develop proniosomal gel for transdermal delivery of 
candesartan cilexetil by using different grades of non 
ionic surfactants. All the proniosomal gel formulations 
were evaluated for the vesicle size, shape, encapsulation 
efficiency, in vitro drug diffusion study, and ex vivo 
permeation study and the results were found in the 
acceptable range. Vesicle size was decreased with 
increasing concentration of cholesterol and 
encapsulation of drug was increased with increasing 
concentration of cholesterol but drug release was  
retarded with increase in concentration of cholesterol. 
Among all the formulations  PNF7 (span 60, soya 
lecithin, and cholesterol present in 9:9:2 ratio) was 
selected as  an optimised formulation, due to low vesicle 
size, high encapsulation efficiency, and released the 
drug  in a controlled manner for extended period of 
time. Overall, these findings indicate that proniosomal 
gel will be promising drug delivery system for 
candesartan cilexetil.  
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